Healthcare company Sonoma Pharmaceuticals (SNOA) has been developing innovative products, but it reported disappointing financials in the fiscal first quarter. So, let’s find out if it is wise to add the stock to your portfolio now.Global healthcare leader Sonoma Pharmaceuticals, Inc.’s (SNOA) shares soared to hit their 52-week high of $15.19 on December 11, 2020, after entering into an exclusive partnership with Crown Laboratories in connection to its Microcyn skincare products. However, the stock has lost 9.3% over the past month and 22.8% over the past three months to close Friday’s trading session at $5.67.
Moreover, its shares are highly volatile, and the company also reported disappointing financials in the fiscal first quarter. It reported losses in the quarter, and its top line also decreased. In addition, its debt could widen in the upcoming months. So, SNOA’s near-term prospects look bleak.
Here’s what could influence SNOA’s performance in the upcoming months: